• Teva Page Title

Korporativne novice

Opomba: novice so v angleškem jeziku, povezave vodijo na korporativno stran podjetja Teva.

23.05.2018

Teva Confirms September PDUFA Date for Fremanezumab

JERUSALEM--(BUSINESS WIRE)--May 23, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today confirmed that the U.S. Food and Drug Administration (FDA) has extended the goal date of the Biologics License Application (BLA) for fremanezumab, an investigational therapy for the preventive treatment of migraine. The Prescription Drug User Fee Act (PDUFA) action date for fremanezumab is set for September 16, 2018. There are no additional data requests from the FDA. “Our primary goal is to bring preventive treatment options to migraine patients as quickly as possible,” said Hafrun Fridriksdottir, Executive V...
15.05.2018

Teva Announces Publication of Phase III Trial Data of Fremanezumab for the Preventive Treatment of Episodic Migraine in the Journal of the American Medical Association

JERUSALEM--(BUSINESS WIRE)--May 15, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the publication of data from the Phase III HALO study evaluating the efficacy, safety, and tolerability of both quarterly (every three months) and monthly subcutaneous dosing regimens of fremanezumab for the prevention of episodic migraine (EM). These pivotal data were published online today by The Journal of the American Medical Association (JAMA). Fremanezumab is a monoclonal antibody that selectively targets CGRP (calcitonin gene-related peptide), a neuropeptide involved in the pathophysiology of migraine. The study evaluated the use of both quarterly and monthly dos...
03.05.2018

Teva Reports First Quarter 2018 Financial Results

Revenues of $5.1 billion Free cash flow of $1.9 billion GAAP EPS of $1.03 Non-GAAP EPS of $0.94 Restructuring plan on-track to achieve $1.5 billion of savings in 2018 and $3.0 billion by the end of 2019 Raising 2018 full year guidance: Non-GAAP EPS guidance raised to $2.40-2.65 from $2.25-2.50 Free cash flow guidance raised to $3.0-3.2 billion from $2.6-2.8 billion JERUSALEM--(BUSINESS WIRE)--May 3, 2018-- Teva Pharmaceutical I...
02.05.2018

Teva to Present AUSTEDO® (deutetrabenazine) Tablets Data at the American Psychiatric Association 2018 Annual Meeting

Three abstracts evaluate the long-term safety and efficacy of AUSTEDO® (deutetrabenazine) tablets for the treatment of tardive dyskinesia in adults In addition, new health economics data assess quality of life and health burden impact among patients JERUSALEM--(BUSINESS WIRE)--May 2, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced new scientific abstracts for AUSTEDO® (deutetrabenazine) tablets will be presented at the American Psychiatric Association (APA) 2018 Annual Meeting in New York from May 5-9. The studies shared at the meeting continue to grow the comprehensive body of ...
27.04.2018

Teva Presents New Long-Term Data Demonstrating Efficacy and Safety of COPAXONE® (glatiramer acetate injection) 40 mg/mL

Up to 7-year efficacy, safety and tolerability results from the GALA open-label extension study presented at the 70th Annual Meeting of the AAN Over seven years, COPAXONE® 40 mg/mL provides consistent, long-term efficacy and safety JERUSALEM--(BUSINESS WIRE)--Apr. 27, 2018-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced up to 7-year efficacy, safety and tolerability results from the Glatiramer Acetate Low-Frequency Administration (GALA) open-label extension study of COPAXONE® (glatiramer acetate injection) 40 mg/mL administered subcutaneously three-times-a-week for the treatm...
23.04.2018

Teva to Report First Quarter 2018 Financial Results on May 3, 2018

JERUSALEM--(BUSINESS WIRE)--Apr. 23, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will release its first quarter 2018 financial results on Thursday, May 3, 2018 at 7:00 a.m. ET. Teva will host a conference call and live webcast on the same day, at 8:00 a.m. ET to discuss its first quarter 2018 results and overall business environment. A Question & Answer session will follow this discussion. In order to participate, please dial the following numbers (at least 10 minutes before the scheduled start time): United States          1-866-254-0808 ...
19.04.2018

Teva and the Procter & Gamble Company Have Agreed to Terminate the PGT Healthcare Partnership

JERUSALEM--(BUSINESS WIRE)--Apr. 19, 2018-- Teva Pharmaceutical Industries [NYSE and TASE: TEVA] has announced that Teva and the Procter & Gamble Company [NYSE: PG] have agreed to terminate the PGT Healthcare partnership that the two companies established in 2011 to market OTC (Over The Counter) medicines. The separation is planned to take effect July 1, 2018 subject to receipt of applicable regulatory approvals. No significant (material) net financial transfer between Teva and P&G will result from the dissolution. PGT Healthcare has grown into a significant presence in over 50 countries, mainly in Europe and Asia, using ...
17.04.2018

Teva to Present New Data Across Multiple Therapeutic Areas at 70th Annual Meeting of the American Academy of Neurology

Two platform presentations and 19 posters explore the potential of fremanezumab as an investigational treatment option for the prevention of migraine COPAXONE® (glatiramer acetate injection) and AUSTEDO® (deutetrabenazine) tablets data highlight Teva’s ongoing clinical research JERUSALEM--(BUSINESS WIRE)--Apr. 17, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced 38 scientific abstracts across five difficult-to-treat disorders of the central nervous system will be presented at the 70th Annual Meeting of the American Academy of Neurology (AAN) in Los Angeles from Apr...
26.03.2018

Teva Announces the Launch of a Generic Version of Lialda® in the United States

JERUSALEM--(BUSINESS WIRE)--Mar. 26, 2018-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of Lialda®1 (mesalamine) delayed-release tablets, 1.2 g, in the U.S. Mesalamine delayed-release tablets are indicated for the induction of remission in adults with active, mild to moderate ulcerative colitis and for the maintenance of remission of ulcerative colitis. “The launch of mesalamine is a significant addition to Teva’s generic portfolio,” said Brendan O’Grady, Executive Vice President and head of North America Commercial at Teva. “With more than a million p...
23.03.2018

Teva Announces the Launch of a Generic Version of ALOXI® in the United States

JERUSALEM--(BUSINESS WIRE)--Mar. 23, 2018-- Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) today announced the launch of a generic version of ALOXI®1 (palonosetron HCI) injection, 0.25 mg/5 mL, in the United States. Palonosetron hydrochloride injection—in a class of medications called 5-HT3 receptor antagonists—is used in adults to prevent nausea and vomiting that may occur as a result of receiving cancer chemotherapy with a moderate or high risk of causing nausea and vomiting. It is also given to prevent nausea and vomiting up to 24 hours after surgery. “The shared-exclusive launch of palonosetron HCI injection...